February 23-24, 2005 BIO CEO and Investor Conference - 500 Beiträge pro Seite

[[KERN]Codex]

=> http://ceo.bio.org/opencms/ceo2005/index.jsp

Focus Sessions:


A Heart to Heart Discussion on Cardiovascular Therapies

Wednesday, February 23, 2005
4:00 PM
Basildon Room

Last year (2004) was a pivotal year for many new and exciting approaches to treating cardiovascular disease. This panel will discuss the impact of last year`s regulatory decisions, the current regulatory environment for cardiovascular drugs, and what is on the horizon for 2005 and 2006.

Moderator:

Corey Davis, PhD; Senior Analyst , Specialty Pharmaceuticals, JP Morgan
Panelists:

Dr. Michael Loberg Ph.D.; CEO, NitroMed, Inc.
Dr. Eldon Smith; Vice President of Scientific Affairs, Vasogen Inc.
Dr. Albert D. Friesen; President & CEO, Medicure Inc.

--------------------------------------------------------------------------------


Advances in Obesity Drugs

Thursday, February 24, 2005
4:00 PM
Basildon Room

Recent high-value partnerships with pharmaceuticals companies offer a glimpse at the need for improvements in treatments for obesity. Join this panel to discuss which product candidates and drug targets are the most likely to deliver value in this high stakes arena.

Moderator:

Reid Leonard, PhD; Senor Director, Scientific Liaison, External Scientific Affairs, Merck & Co., Inc.
Expert:

Donna H. Ryan, MD; Professor, Pennington Biomedical Research Center, Baton Rouge,Louisiana
Panelists:

Dr. Alain Baron M.D.; Senior Vice President, Research, Amylin Pharmaceuticals, Inc.
Dominic Behan Ph.D.; Senior Vice President & CSO, Arena Pharmaceuticals, Inc.
Roland Scollay Ph.D.; Chief Executive Officer, Metabolic Pharmaceuticals Limited
Dr. Steven C. Quay; President and CEO, Nastech Pharmaceutical Company Inc.

--------------------------------------------------------------------------------


Advances in Sexual Dysfunction and Hormone Therapies

Thursday, February 24, 2005
9:30 AM
Louis XVI Suite Center/West

Viagra has proven that blockbuster markets exist for specific categories of sexual dysfunction, but many other indications remain unaddressed or are just now being recognized. This panel will address male and female sexual dysfunction programs as well as recent clinical and regulatory developments in the field of hormone therapies.

Moderator:

Angela Larson; Managing Director, C.E. Unterberg, Towbin
Expert:

Marc Gittelman, MD, FACS; Director, Miami Center for Sexual Health
Panelists:

Mr. Stephen M. Simes; President and CEO, BioSante Pharmaceuticals, Inc.
Y. Joseph Mo Ph.D.; CEO and President, NexMed, Inc.
Gerri Henwood; Chief Executive Officer, Auxilium Pharmaceuticals, Inc
Robert J. DeLuccia; President and Chief Executive Officer, MacroChem Corporation

--------------------------------------------------------------------------------


Biomarkers and Drugs: A Happy Marriage?

Wednesday, February 23, 2005
9:30 AM
Conrad Suite

The FDA is starting to demand biomarkers that can predict drug response. How is the industry meeting this demand and what technologies and tools are being developed to help the industry achieve this goal?

Moderator:

Catherine Wheeler, MD; VP Global Product Director, Oncology, AstraZeneca Pharmaceuticals LP
Expert:

Karen Buchovich, PhD; Research Associate, J P Morgan Securities Inc.
Panelists:

Mr. Kevin Hrusovsky; President and CEO, Caliper Life Sciences
Dr. William E. Rich Ph.D.; Chief Executive Officer, Ciphergen Biosystems, Inc.
Dr. Thomas J. Colatsky Ph.D.; VP, Healthcare Research, Icoria, Inc.
Kenneth Carter Ph.D.; President & CEO, Avalon Pharmaceuticals, Inc.

--------------------------------------------------------------------------------


Biotech and Eye Disorders: Seeing Beyond the Obvious

Thursday, February 24, 2005
9:30 AM
Conrad Suite

Ocular diseases have gained great attention in recent years with treatments for diseases of AMD. Yet despite the buzz, most ophthalmic indications remain underserved, granting the opportunity for our industry to provide innovative solutions. New solutions for glaucoma, macular degeneration, dry eye and other areas will be discussed in this panel.

Moderator:

Jason Kantor, PhD; Analyst, WR Hambrecht + Co
Expert:

Janet Conway, PhD; Director, Licensing and Development, Pfizer Inc.
Panelists:

Kim Brazzell Ph.D.; Senior Vice President of Ophthalmic Research and Development, Inspire Pharmaceuticals, Inc.
Vicente Anido, Jr. Ph.D.; President and CEO, ISTA Pharmaceuticals
Paul Hastings; President and CEO, QLT, Inc.
Roy Clifford Levitt M.D., Ph.D.; President and CEO, Genaera Corporation

--------------------------------------------------------------------------------


Biotech`s Solutions to Alzheimer`s and Parkinson`s Disease

Wednesday, February 23, 2005
9:30 AM
Basildon Room

The holy grail for our healthcare system would be a cure for Alzheimer`s and/or Parkinson`s disease. This panel will provide a clinical perspective on the problem and opportunities that are being explored towards finding a cure.

Moderator:

Elemer Piros, PhD; Senior Biotechnology Analyst, Rodman & Renshaw
Expert:

Dr. Jeremy Levin; Global Head of Strategic Alliances, Novartis
Panelists:

Jeffrey M. Ostrove Ph.D.; President & CEO, Ceregene Inc.
Tony Scullion; Chief Executive Officer, Memory Pharmaceuticals
Dr. William Wheeler M.D.; Vice President and Chief Medical Officer, Aderis Pharmaceuticals, Inc.
Jonas V. Alsenas DVM; Chief Executive Officer, Prana Biotechnology, Limited
Jack Barber Ph.D.; Senior Vice President, Drug Development, CytRx Corporation

--------------------------------------------------------------------------------


Breathtaking New Respiratory Drugs for COPD, Asthma and Allergies

Thursday, February 24, 2005
4:00 PM
Duke of Windsor

In 2002, the cost of drug treatments for asthma and COPD exceeded $12 billion, but this figure is dwarfed by the economic impact of the diseases. This panel will explore changes in current treatment regimens and introduce approaches on the horizon to treating COPD, asthma and allergic rhinitis.

Moderator:

Brian Lian, PhD; Senior Analyst, Biotechnology, Fortis Securities LLC
Expert:

Marianne Mann, MD; Clinical Drug Development & Regulatory Consultant
Panelists:

Mr. Steve Gillis; Chairman and CEO, Corixa Corporation
James M. Gower; Chairman & CEO, Rigel Pharmaceuticals, Inc.
Dr. Dino Dina M.D.; President and CEO, Dynavax Technologies Corporation
Dr. Paul Rubin; President, CEO and Director, Critical Therapeutics, Inc.

--------------------------------------------------------------------------------


Cure the Pain- Reap the (Overlooked) Gain

Wednesday, February 23, 2005
4:00 PM
Louis XVI Suite Center/West

Pain is currently one of the fastest growing therapeutic segments. Its growth rate is expected to exceed 20%. There are over 50 new drugs in development that include new formulations of older drugs and new targeted therapies with fewer side effects. This panel will discuss the need for better drugs and look to what is new on the horizon.

Moderator:

Will Rowe; Executive Director, American Pain Foundation
Expert:

David A.H. Lee, MD, PhD; Executive Vice President, Research & Development and Chief Scientific Officer, Endo Pharmaceuticals
Panelists:

Warren Stern Ph.D.; Senior VP, Drug Development, DOV Pharmaceutical, Inc.
Ms. Donna Shum; CEO, North America, Wex Pharmaceuticals Inc.
Ronald W. Eastman; Chief Executive Officer, Rinat Neuroscience
Alan W. Dunton M.D.; President and Chief Executive Officer, Metaphore Pharmaceuticals, Inc.

--------------------------------------------------------------------------------


Diabetes: An Epidemic Growing Younger

Thursday, February 24, 2005
9:30 AM
Basildon Room

This panel will explore new solutions to diabetes, a disease which continues to grow in prevalence as our population increases. The biotech industry is spearheading many of the new therapeutic candidates and delivery mechanisms, offering solutions to the burgeoning markets for new treatments and providing attractive partnering opportunities to pharmaceutical companies.

Moderator:

Steven Delco; President, Delco Advisors
Expert:

Alan Moses, MD; Associate Vice President, Medical Affairs, Novo Nordisk Inc.
Panelists:

Dr. Elliot Ehrich M.D.; Chief Medical Officer, Alkermes, Inc.
Dr. Alain Baron M.D.; Senior Vice President, Research, Amylin Pharmaceuticals, Inc.
Dr. Stanley T. Crooke M.D., Ph.D.; CEO and Chairman of the Board, Isis Pharmaceuticals, Inc.
Guenther Karmann; CEO, DeveloGen AG
Dr. Gordana Kosutic M.D.; Vice President, Clinical and Regulatory Affairs, NOBEX Corporation

--------------------------------------------------------------------------------


Drug Development: Finding Gold in Other Drugs

Wednesday, February 23, 2005
4:00 PM
Park Avenue Suite Center/North

Perhaps what may not be worth developing to one company may be a blockbuster for another. It may be the original indication that changes or just a newly committed development team that make a drug candidate a promising prospect. Join this panel to learn more about methods that generate exciting new therapeutics from old molecules.

Moderator:

M. Sharon Webb, MD, PhD; Attorney, Goodwin Procter LLP
Expert:

Alan Walton; Chairman, Oxford BioScience Partners
Panelists:

Clive Meanwell M.D.; Chairman and Chief Executive Officer, The Medicines Company
Duncan Higgons; Chief Commercial Officer, Transform Pharmaceuticals, Inc.
Jay D. Kranzler MD, PhD; Chairman & CEO, Cypress Bioscience, Inc.
Gary Steven Jacob; CEO, Callisto Pharmaceuticals Inc.

--------------------------------------------------------------------------------


Fighting the Enemy Within: Psoriasis, RA and Lupus

Wednesday, February 23, 2005
9:30 AM
Duke of Windsor

More than 50 million Americans suffer from autoimmune diseases. Although there are many types of autoimmune diseases, the most prevalent are rheumatoid arthritis, lupus and psoriasis. This panel will discuss the challenges of developing new drugs that target autoimmune disorders.

Moderator:

Winson Tang, MD, FACP; Director of Research, Pacific Capital Group
Expert:

Alisa Koch, MD; Frederick G.L. Huetwell and William D. Robinson, MD Professor of Rheumatology, University of Michigan Medical School
Panelists:

Dr. Akshay Vaishnaw M.D.; Senior Director of Medical Research, Biogen Idec Inc.
Dr. Randall W. Yatscoff; President and Chief Operating Officer, Isotechnika Inc.
Steven B. Engle; Chairman and CEO, La Jolla Pharmaceutical Company

--------------------------------------------------------------------------------


Gene Therapy: Are We There Yet? Are We There Yet?

Wednesday, February 23, 2005
4:00 PM
Conrad Suite

Gene therapy offers promise for many of the most serious diseases, yet it has faced more developmental and regulatory challenges than almost any other therapeutic modality. This panel will explore the issues surrounding the development of gene therapy drugs today.

Moderator:

Navdeep Jaikaria; Director of Equity Research, Managing Director, Senior Equity Research Analyst, Rodman & Renshaw
Experts:

Savio L.C. Woo, PhD; Professor and Chair of Gene and Cell Medicine, Mount Sinai School of Medicine, Institute of Gene Therapy and Molecular Medicine
Alan E. Smith, PhD; Senior Vice President, Research and Chief Scientific Officer, Genzyme
Panelists:

Richard E. Otto; President and CEO, Corautus Genetics
Paul H. Fischer Ph.D.; President and Chief Executive Officer, GenVec, Inc.
Ms. H. Stewart Parker; President and Chief Executive Officer, Targeted Genetics Corporation

--------------------------------------------------------------------------------


Hepatitis: The Silent Killer

Wednesday, February 23, 2005
9:30 AM
Louis XVI Suite Center/West

Hepatitis is a highly infectious and silent disease that eats away at your liver. Current treatments can be effective, but with multiple side-effects. With a clearer understanding of the virus and how it affects the body, the industry has developed several innovative approaches to combat the virus. This panel will provide a clinician`s perspective of what is needed to combat this disease and discuss emerging new treatments.

Moderator:

Jim Reddoch; Biotech Analyst, Friedman, Billings, Ramsey
Expert:

Scott Friedman, MD; Chief of Liver Diseases, Division of Medicine, Mount Sinai Medical Center and Medical School
Panelists:

Jean-Pierre Sommadossi; Founder, Chairman & CEO, Idenix Pharmaceuticals, Inc.
Steven J. Mento Ph.D.; President & CEO, Idun Pharmaceuticals, Inc.
Dr. Carol Brosgart M.D.; Vice President of Clinical Research, Gilead Sciences, Inc.
Dr. Joshua Boger Ph.D.; Chairman & CEO, Vertex Pharmaceuticals Incorporated

--------------------------------------------------------------------------------


HIV: The War Against Resistance

Wednesday, February 23, 2005
4:00 PM
Duke of Windsor

Join this panel to explore one of the critical aspects of infectious disease treatment today, the antiretroviral resistant strains of the human immunodeficiency virus. Identifying and addressing specific resistant and cross-resistant strains of HIV is central to the treatment of HIV-infected patients since second-line treatments are limited by the resistance profiles of the particular HIV mutation.

Moderator:

William Tanner, PhD; Managing Director, Director of Equity Research, Leerink Swann & Company
Expert:

Stephen M. Smith, MD; Chief & Program Director, Infectious Diseases, St. Michael`s Medical Center, Seton Hall University School of Graduate Medical Education
Panelists:

Dr. John C. Pottage M.D.; Vice President, Drug Development, Achillion Pharmaceuticals, Inc.
Michael Hitchcock Ph.D.; Vice President, Medical Affairs, Gilead Sciences, Inc.
Dr. John N. Bonfiglio Ph.D.; President & CEO, The Immune Response Corporation
Dr. Stanley Lewis; Medical Director, Tanox, Inc.

--------------------------------------------------------------------------------


New Antibiotics Against New and Old Threats

Thursday, February 24, 2005
9:30 AM
Duke of Windsor

New antibiotics today face new market dynamics to capture a high-value prize. Join this panel to discuss the new market dynamics and new agents against specific pathogens in the quest to conquer serious infectious diseases.

Moderator:

Dallas J. Webb; Senior Vice President, Equity Research, Stanford Group Company
Expert:

Steven J. Projan, PhD; Vice President, Biological Technologies, Wyeth Research
Panelists:

Rick Winningham; CEO, Theravance, Inc.
Michael W. Bonney; President & CEO, Cubist Pharmaceuticals, Inc.
Susan Froshauer, PhD; President and CEO, Rib-X Pharmaceuticals
Roger Echols, M.D.; Chief Medical Officer, Replidyne, Inc.

--------------------------------------------------------------------------------


New Inroads to Treating Gastrointestinal Disorders

Thursday, February 24, 2005
4:00 PM
Louis XVI Suite Center/West

With the advent of new biologic treatments to address serious gastrointestinal (GI) disorders and the emergence of several promising new therapeutic approaches, the environment for treating these debilitating conditions is shifting dramatically. At the same time, a perception of increased prevalence and patient population size is driving interest and investment in exploring new targets and agents. These new agents are among the first to focus on the inflammatory and functional disease targets underlying Irritable Bowel Syndrome, Crohn?s disease and ulcerative colitis, and promise new hope for the more effective treatment of GI?related conditions. This panel will discuss where the market growth, and clinical and scientific frontiers lie in developing solutions to improve treatment of this underserved patient population.

Moderator:

Michael G. King; Managing Director and Senior Equity Research Analyst, Banc of America Securities LLC
Expert:

Lloyd F. Mayer, MD; Chief, Division of Gastroenterology, The Mount Sinai Medical Center
Panelists:

Lee R. Brettman M.D.; President and CEO, Dynogen Pharmaceuticals, Inc.
Thomas Schall Ph.D.; President and CEO, ChemoCentryx, Inc.
Peter E. Callegari M.D.; Executive Director of Medical Affairs, Centocor, Inc.
Richard Y. Chin M.D.; Senior Vice President, Global Medical Affairs, Elan Biopharmaceuticals

--------------------------------------------------------------------------------


Orphan Drugs: Gaining Broader Adoption?

Thursday, February 24, 2005
4:00 PM
Conrad Suite

Biotech companies have produced many successful drugs through the Orphan Drug Program to combat serious diseases and create markets never expected. Join this panel to discuss where these blockbuster opportunities remain and which companies are developing new treatments for the most underserved diseases.

Moderator:

Aaron S. Reames; Senior Vice President, Equity Research, Stanford Group Company
Expert:

Abbey Myers; President, National Organization for Rare Disorders
Panelists:

David Keiser; President, Alexion Pharmaceuticals, Inc.
Michael E. Hart; President and CEO, Allos Therapeutics, Inc.
Ted W. Love Ph.D.; President and CEO, Nuvelo, Inc.
Gary Steven Jacob; CEO, Callisto Pharmaceuticals Inc.
Sean Thompson; Director, Corporate Development, YM BioSciences Inc.
Stuart Peltz Ph.D.; President and CEO, PTC Therapeutics, Inc.

--------------------------------------------------------------------------------


Personalized Medicine: From Bench to Bedside

Wednesday, February 23, 2005
9:30 AM
Park Avenue Suite Center/North

Personalized medicine and pharmacogenomics represent great promise for transforming the delivery and effectiveness of 21st century medicine. This panel will discuss several approaches to PM including ones that can help some of the blockbuster drugs today.

Moderator:

Dirk Lammerts, MD; Vice President, Molecular Diagnostics, Affymetrix, Inc.
Panelists:

Mr Spiro Rombotis; CEO, Cyclacel Ltd
Dr. Charles R. Cantor Ph.D.; Chief Scientific Officer, Sequenom, Inc.
Brad A. Margus; Chief Executive Officer and Co-Founder, Perlegen Sciences, Inc.
Dr. Richard T. Dean Ph.D.; Chief Executive Officer, Xanthus Life Sciences, Inc.

--------------------------------------------------------------------------------


Solid Progress in Combating Solid Tumors

Wednesday, February 23, 2005
9:30 AM
East Foyer

Solid tumor cancers represent over 80% of all cancers and most of today`s drugs show efficacy across a range of tumor types, but with low response rates. This panel will discuss approaches that target tumors based on biomarkers that are demonstrating response rates never seen before.

Moderator:

Anna Kazanchyan, MD; President, AKM Advisory Group, LLC
Expert:

James Holland, MD; Professor of Medicine, Hematology, Medical Oncology, and Professor of Oncological Sciences, Mount Sinai School of Medicine
Panelists:

Dr. Jack Singer M.D.; Chief Medical Officer, Cell Therapeutics, Inc.
Colin Goddard Ph.D.; Chief Executive Officer, OSI Pharmaceuticals, Inc.
Dr. Leonard Post Ph.D.; Senior Vice President of Research and Development, Onyx Pharmaceuticals, Inc.
Dr. William P. Peters M.D., Ph.D., M.B.A.; Chairman and CEO, Adherex Technologies Inc.

--------------------------------------------------------------------------------


Starving Cancer

Thursday, February 24, 2005
9:30 AM
East Foyer

Starving cancer tumors of their blood supply has been the focus of breakthrough discoveries by many companies and leading cancer researchers. This panel will discuss the latest bench approaches and clinical progress of both anti-angiogenesis and vascular targeting agents.

Moderator:

David Wood, PhD; Senior Biotechnology Analyst, Rodman & Renshaw
Expert:

Robert S. Kerbel, PhD; Canada Research Chair in Molecular Medicine, Senior Scientist, Molecular & Cellular Biology, Sunnybrook and Womens College Health Sciences Centre
Panelists:

Dr. Leonard Post Ph.D.; Senior Vice President of Research and Development, Onyx Pharmaceuticals, Inc.
Dr. Dai Chaplin Ph.D.; Chief Scientific Officer, OXiGENE, Inc.
David Hale; President and CEO, CancerVax Corporation
James S. Burns; President & CEO, EntreMed, Inc.

--------------------------------------------------------------------------------


Strategies for Monoclonal Antibody Therapies

Thursday, February 24, 2005
9:30 AM
Park Avenue Suite Center/North

Targeted therapies, especially MAb`s, bring great promise to the treatment of the most serious diseases. This panel will explore strategies for maintaining high approval rates for therapeutic MAb`s in a post-genomic era with a plethora of unproven targets being used, and when most of the validated targets have been evaluated with one or more antibodies.

Moderator:

Maddy Baer; Partner, Brown Raysman Millstein Felder & Steiner LLP
Expert:

Matthew Geller, PhD; Managing Director, Equities Analyst, CIBC World Markets
Panelists:

Jennie P. Mather Ph.D.; Founder, President, and CEO, Raven biotechnologies, inc.
Ed Mathers; VP, Corporate Development, MedImmune, Inc.
Dr. Clay B. Siegall Ph.D.; President and CEO, Seattle Genetics, Inc.
Gary Noon; Senior Vice President, Pharmaceuticals, Diversa Corporation

--------------------------------------------------------------------------------


The Next Wave of Targeted Therapies for Treating Cancer

Wednesday, February 23, 2005
4:00 PM
East Foyer

The validation of new genomic targets is providing new ways to combat cancer. This panel will discuss the various new targets that have emerged to fight cancer including membrane receptors, proteosome and COX-2 inhibitors and epothilones.

Moderator:

Reni J. Benjamin, PhD; Senior Biotechnology Analyst, Rodman & Renshaw
Expert:

Dr. Scott Wadler; Head, Solid Tumor Service, Weill Medical College of Cornell University
Panelists:

Dr. Joseph Vallner Ph.D.; President and Chief Operating Officer, Cell Genesys, Inc.
Mr Spiro Rombotis; CEO, Cyclacel Ltd
Dr. Bernd R. Seizinger M.D., Ph.D.; Chief Executive Officer, GPC Biotech AG
Dan Giampuzzi; President and CEO, Gemin X Biotechnologies Inc.
Dr. Timothy Shannon; Executive VP of Research and Development and CMO, CuraGen Corporation

--------------------------------------------------------------------------------


Zeroing In on the Cure for Cancer with Exciting Approaches

Thursday, February 24, 2005
4:00 PM
East Foyer

The tide is slowly turning in the war against cancer as a new generation of treatments emerge. Many of these approaches are in late-stage development, including vaccines, monoclonal antibodies, gene therapy, etc. This panel will discuss how these new drugs will fit into the current treatment regimens.

Moderator:

Bill Kridel, Jr., JD; Managing Director, Ferghana Partners
Expert:

Tim Cripe, MD, PhD; Division of Hematology & Oncology, Children`s Hospital Medical Center
Panelists:

Dr. David Urdal; Chief Scientific Officer & Vice Chairman of the Board of Directors, Dendreon Corporation
Dr. Jerome B. Zeldis M.D., Ph.D.; Chief Medical Officer and Vice President Medical Affairs, Celgene Corporation
Dr. Dirk Reitsma; Vice President, Clinical Development, Oncology, MedImmune, Inc.
Dr. Judith Hemberger Ph.D.; Vice President and Chief Operating Officer, Pharmion Corporation
David G. Nance; President & CEO, Introgen Therapeutics, Inc.




..so nun wissen alle Bescheid


gruß codex^der seine Augen auch auf einige Unternehmen wirft

[KingKong2]

Schon erstaunlich, daß es auf so einen Beitrag keinerlei Reaktionen gibt!
Die Biotechs sind doch leicht zurückgeblieben und könnten in den kommenden Wochen für einige Überraschungen sorgen. Auch ich habe einige der beteiligten Unternehmen auf der Watchlist. Bei zwei der genannten Unternehmen habe ich mich bereits im Vorfeld postiert.

So long KingKong

[[KERN]Codex]

Frag ich mich auch gerad, eigentlich müsste der Thread gerammelt voll sein

[[KERN]Codex]

huhu

In einer halben Stunde präsentiert sich GERON Geron hier:

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=GER…



=> Heute vorbörslich schon über 7,8$

[[KERN]Codex]

Die Präsentation ist sehr interessant!
Jeder der Interesse an "oncology
und hesc" hat sollte sich das anhören!
Anfang März werden weitere Infos kommen..

[[KERN]Codex]

Naja hier gibt es ja noch viel mehr spannende Präsentationen

Thread bisher nur 164 mal gelesen, seit ihr alle persönlich da ?

[[KERN]Codex]

GERON über 10$